in pictures and a few words
What it is and why it matters
Berberine is a substance from barberry. It has been studied in bacterial overgrowth in the gut and in raised blood sugar in people with type 2 diabetes.
- It is sold as a supplement, but it has a real medicinal effect
- So treat it like a medicine: check the dose, medicines and contraindications
First place in the overall ranking
Researchers pooled many studies of different treatments for bacterial overgrowth. Berberine came first in the overall ranking.
- First place applies when there are no accompanying illnesses
- The authors think it may turn out to be a favourable choice
Comparison with an antibiotic underway
A study is now under way that compares berberine with an antibiotic face to face. It will show whether berberine does no worse than the antibiotic.
- In this study berberine is taken for two weeks, twice a day
Blood sugar and blood fats
In people with type 2 diabetes berberine slightly lowers blood sugar — fasting and two hours later — and one type of blood fat.
- Together with blood-sugar medicines it may help the treatment
- It is not a replacement: don’t stop the medicines you were prescribed
How much berberine is in a capsule
In the study of bacterial overgrowth the dose being tested is 800 mg of berberine a day — 400 mg twice a day.
- A capsule often holds barberry extract rather than berberine itself
- A 500 mg extract capsule holds about 10 mg of berberine, maybe even less
- Look at the milligrams of berberine, not of extract
Raises the level of other medicines
Berberine raises the blood level of some medicines. In people after a kidney transplant it noticeably raised the level of cyclosporine — a medicine that suppresses the immune system.
Important. If you take immune-suppressing medicines, cardiac glycosides, blood thinners or anticonvulsants, berberine is discussed with a doctor.
What may bother you
Most often there is constipation or diarrhoea. A large review rated berberine as safe overall.
Who should see a doctor first
Berberine is not taken during pregnancy or breastfeeding. It should not reach newborns, including through breast milk.
- For a baby the risk is that a jaundice pigment in the blood may reach the brain
- How much berberine passes into milk is unknown — and unknown does not mean safe
Important. Decisions about taking it, the dose and combining it with prescribed treatment are made by a doctor.
In one sentence
Berberine ranked first for uncomplicated bacterial overgrowth, while the comparison with an antibiotic is still running; it also slightly lowers sugar. Its effect is real: check the dose, medicines and contraindications.
- With bloating, check first, then treat — and treat the person, not the test
Key points
In our guide to SIBO berberine appears in a single line — as the intervention that topped a network meta-analysis; here, in detail, is what studies in people showed.
| Situation | How it helps | What human studies showed |
|---|---|---|
| Uncomplicated SIBO | a possible agent for eradication — clearing the bacterial overgrowth | 2025 network meta-analysis (30 RCTs, 1552 participants, 12 interventions): berberine had the highest SUCRA value — first place on ranking probability (the data on it come from one trial of 46 people); the authors call it a potentially favourable option for SIBO eradication (PMID 41394885[1]) |
| Type 2 diabetes: blood glucose | berberine alone lowers fasting and 2-hour glucose | 2024 meta-analysis (50 trials, 4150 participants): fasting glucose −0.59 mmol/L (−11 mg/dL), 2-hour glucose −1.57 mmol/L (−28 mg/dL) (PMID 39640489[2]) |
| Triglycerides | berberine alone lowers triglycerides | −0.35 mmol/L (−31 mg/dL) in the same meta-analysis |
| Alongside glucose-lowering drugs | may assist prescribed treatment | in the same meta-analysis fasting glucose −0.99 mmol/L (−18 mg/dL), 2-hour glucose −1.07 mmol/L (−19 mg/dL), HbA1c −0.69% |
How it helps
First place in the SIBO ranking
The source is a 2025 network meta-analysis (PMID 41394885[1]): 30 randomised trials, 1552 participants, 12 different interventions, with the protocol registered in PROSPERO. It gathers trials that never overlapped with each other into a single network and arranges the interventions into a ranking.
Berberine received the highest SUCRA value in that ranking — 82.5%. The data on it in this network come from one trial of 46 people, a direct comparison with rifaximin: berberine was numerically higher, and the difference was not statistically significant. The authors write that this positions it as a potentially favourable option for SIBO eradication.
The comparison with rifaximin
The head-to-head is already under way. The BRIEF-SIBO trial (PMID 36873985[3]): 180 patients, berberine against rifaximin, 400 mg twice daily for two weeks, six weeks of follow-up, primary outcome a negative breath test. The stated hypothesis is that berberine is not inferior to rifaximin. An interim analysis in 46 people supported it: berberine was not inferior to rifaximin (conference abstract, 2024). Final results are awaited.
Metabolism
The second reason to be interested is metabolism, and the evidence base there is considerably larger. A 2024 meta-analysis pooled 50 trials and 4150 participants (PMID 39640489[2]); the results are in the «Key points» table.
The detailed comparison with metformin is covered separately — berberine or metformin, on mechanisms, doses and how the side-effect profiles differ.
How to take it
The dose studied in SIBO is 800 mg of berberine a day: in the BRIEF-SIBO trial that is 400 mg twice daily for two weeks. In metabolic research the usual range is 0.9–1.5 g a day for one to three months.
Now look at what a supplement actually contains. Very often it is not berberine but barberry extract standardised to 2% berberine. Which means a «500 mg» capsule holds roughly 10 mg of the active compound. And the label usually reads «up to 2%» — a ceiling rather than a promise: the real figure may be lower.
The practical rule in one line: look at the milligrams of berberine, not the milligrams of extract. If the package gives only the weight of the extract and the percentage of standardisation, multiply them.
Who should see a doctor first
Berberine is sold as a supplement, but it has at least three properties that in a pharmacy medicine would land in the contraindications section.
1. It raises the levels of other drugs
The weightiest evidence is not laboratory work but people. A randomised trial in renal transplant recipients (PMID 16133554[4]): 52 patients took cyclosporine together with berberine, 52 without it, for three months.
| Cyclosporine measure | Change with berberine |
|---|---|
| Area under the curve (AUC) | +34.5% |
| Trough concentration | +88.3% |
| Half-life | +2.7 hours |
| Clearance | −40.4% |
For a drug with a narrow therapeutic window that is a great deal. In animal work (PMID 19370549[5]) berberine likewise increased digoxin absorption — the area under the curve reached 170% of control, and only with oral dosing, meaning the effect is intestinal.
Hence the rule: if you take immunosuppressants, cardiac glycosides, anticoagulants or anticonvulsants, berberine is discussed with a physician, not added alongside them.
2. Pregnancy, breastfeeding and newborns
Who must not take it: pregnancy, breastfeeding, newborns.
Berberine displaces bilirubin from its binding to albumin. In a laboratory study (PMID 8513024[6]) it proved, on a molar basis, about tenfold more potent than phenylbutazone — a known displacer of bilirubin.
For an adult that carries little weight. For a newborn it is a risk of free bilirubin reaching the brain. The US National Institutes of Health lactation database puts it plainly: most sources recommend avoiding newborn exposure to berberine, including through breast milk — and honestly adds that the extent of transfer from mother to infant is unknown.
3. The ordinary side effects
A 2023 umbrella review pooling eleven meta-analyses (PMID 36999891[7]) names constipation and diarrhoea as the common gastrointestinal effects. Overall it rates berberine as a safe ingredient.
Bottom line
Berberine is a compound with real pharmacology: in uncomplicated SIBO it topped a network meta-analysis ranking, a head-to-head comparison with rifaximin is already running, and in metabolism it slightly lowers glucose and triglycerides and may assist prescribed treatment. That is exactly why it deserves to be treated like a medicine: check the dose, check the interactions, check the contraindications.
And the thing worth taking away even if the rest is forgotten: with bloating, what decides the outcome is not the choice of agent but the order of steps — check first, then treat, and treat the person rather than the test.
References
Key facts
- In a 2025 network meta-analysis (30 RCTs, 1552 participants, 12 interventions) berberine had the highest SUCRA in uncomplicated SIBO (the data on it come from one trial of 46 people, a direct comparison with rifaximin); the authors call it a potentially favourable option for SIBO eradication.
- A head-to-head trial is already under way: BRIEF-SIBO, 180 patients, berberine 400 mg twice daily against rifaximin for two weeks, primary outcome a negative breath test.
- A 2024 meta-analysis (50 trials, 4150 participants): berberine alone lowered fasting glucose by 0.59 mmol/L (11 mg/dL), 2-hour glucose by 1.57 mmol/L (28 mg/dL) and triglycerides by 0.35 mmol/L (31 mg/dL); alongside glucose-lowering drugs HbA1c fell by 0.69%.
- The studied dose is 800 mg of berberine a day. Supplements often contain an extract standardised to 2% berberine: 500 mg of such an extract gives about 10 mg of the active compound.
- Berberine raises cyclosporine levels in humans: AUC +34.5%, trough concentration +88.3% (a randomised trial in 104 patients). With immunosuppressants, cardiac glycosides, anticoagulants or anticonvulsants, berberine is discussed with a physician.
